Drug intelligence / Profile preview

Maculife

Development stage: Unknown
Lead developer: Farmigea
Modality: Small Molecules
Administration: Oral

Overview

Maculife is a multi-ingredient dietary supplement developed by Farmigea S.p.A. for the management of retinal disorders and the maintenance of visual health. It is formulated as oral capsules containing a synergistic blend of antioxidants and nutrients, including lutein, zeaxanthin, docosahexaenoic acid (DHA), tocotrienols, vitamin C, vitamin E, zinc, and copper. These components work to protect the retinal pigment epithelium and photoreceptors from oxidative damage and the harmful effects of high-energy blue light. While some clinical databases may incorrectly categorize it as a topical ophthalmic formulation, Maculife is commercially available as an oral nutraceutical indicated for conditions such as age-related macular degeneration (AMD).

Brand names: Maculife

Targets

Misfolded SOD1

Beyond the preview

Go deeper on Maculife.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maculife.

Explore the full profile